Xylem (XYL) Stock Price Target 2026

The average analyst price target for Xylem is $131.59, 32.6% above the current price. Of 15 analysts, 10 rate it Buy, 4 Hold and 1 Sell. Targets range from $90 to $175. The latest change came on Nov 4, 2026, when Argus Research downgraded Xylem from Buy to Hold.

The Average Analyst Price Target for Xylem is $131.59.

Price Target Range — 13 Quarters

Analyst Consensus — 15 Analysts

10Buy

4Hold

1Sell

Consensus RatingOutperform# Analysts15Avg. Consensus PT$131.59Upside to Avg. PT+32.6%

Rating Trend — Last 9 Months

Latest Upgrades and Downgrades for Xylem Stock

See all ratings →

Date	Firm	Analyst	Action	Rating Change	Price Target
Nov 4, 2026	Argus Research	John Eade	Downgrade	Buy→Hold	—
Oct 29, 2026	UBS	Joshua Spector	PT Cut	Neutral	$112→$99
Oct 29, 2026	Barclays	William Grippin	Downgrade	Overweight→Equal-Weight	$139→$104
Oct 28, 2026	Citigroup	Andrew Kaplowitz	PT Cut	Buy	$148→$130
Oct 28, 2026	BNP Paribas	Andrew Buscaglia	PT Cut	Outperform	$145→$135
Oct 28, 2026	Goldman Sachs	Brian Lee	PT Cut	Buy	$160→$138
Oct 28, 2026	Stifel	Nathan Jones	PT Cut	Buy	$141→$114
Oct 28, 2026	RBC Capital	Jeffrey Reive	PT Cut	Outperform	$135→$125
Oct 28, 2026	Oppenheimer	Bryan Blair	PT Cut	Outperform	$150→$135
Oct 28, 2026	JP Morgan	Michael Fairbanks	Downgrade	Neutral→Underweight	$118→$90
Oct 19, 2026	JP Morgan	Mark Strouse	PT Cut	Neutral	$137→$118
Oct 15, 2026	Mizuho	Brett Linzey	PT Cut	Neutral	$130→$110
Oct 14, 2026	Oppenheimer	Bryan Blair	PT Cut	Outperform	$158→$150
Oct 14, 2026	RBC Capital	Jeffrey Reive	PT Cut	Outperform	$164→$135
Oct 13, 2026	Barclays	William Grippin	PT Cut	Overweight	$159→$139
Oct 12, 2026	Citigroup	Andrew Kaplowitz	PT Cut	Buy	$172→$148
Oct 5, 2026	UBS	Joshua Spector	PT Cut	Neutral	$138→$112
Sep 15, 2026	Wolfe Research	Nigel Coe	Assumes	Peer Perform	—
Aug 24, 2026	Jefferies	Stephen Volkmann	PT Raise	Buy	$145→$150
Aug 13, 2026	UBS	Joshua Spector	PT Raise	Neutral	$135→$138